These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 21389095)

  • 1. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.
    Bleul CC; Farzan M; Choe H; Parolin C; Clark-Lewis I; Sodroski J; Springer TA
    Nature; 1996 Aug; 382(6594):829-33. PubMed ID: 8752280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
    Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
    J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
    Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
    Oberlin E; Amara A; Bachelerie F; Bessia C; Virelizier JL; Arenzana-Seisdedos F; Schwartz O; Heard JM; Clark-Lewis I; Legler DF; Loetscher M; Baggiolini M; Moser B
    Nature; 1996 Aug; 382(6594):833-5. PubMed ID: 8752281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4.
    Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M
    Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages.
    Münch J; Ständker L; Pöhlmann S; Baribaud F; Papkalla A; Rosorius O; Stauber R; Sass G; Heveker N; Adermann K; Escher S; Klüver E; Doms RW; Forssmann WG; Kirchhoff F
    Antimicrob Agents Chemother; 2002 Apr; 46(4):982-90. PubMed ID: 11897579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
    Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
    Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
    J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
    Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
    J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.